David Guyer biography

Dr. David R. Guyer M.D. serves as Non-Executive Director of the Company. Dr David Guyer MD is a long-standing member of the US retina community and is currently the Co-Founder and Executive Chairman of IVERIC bio (formerly Ophthotech Corporation). He was previously the CEO of Ophthotech. Dr Guyer is also on the Boards of Sound Pharmaceuticals, iStar Medical, PanOptica, Selphagy Therapeutics, EyePoint Pharmaceuticals and Visus Therapeutics. He co-founded and served as CEO and a Director of Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings, and oversaw the rapid development and successful commercialization of MacugenR (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for the treatment of wet AMD. Dr Guyer has also had a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr Guyer received his Bachelor of Science (BSc) degree from Yale College summa cum laude and his medical degree (MD) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

What is the salary of David Guyer?

As the Non-Executive Director of Oxurion NV, the total compensation of David Guyer at Oxurion NV is €34,000. There are 4 executives at Oxurion NV getting paid more, with Patrik De Haes having the highest compensation of $557,000.